版本:
中国

BRIEF-pSivida announces positive 12-month follow-up data for Durasert three-year treatment for posterior segment uveitis

May 8 Psivida Corp

* Psivida corp- durasert™ three-year treatment for posterior segment uveitis significantly reduces recurrences through 12 months

* Psivida corp- psivida anticipates reporting top line results from second pivotal phase 3 clinical trial in june 2017

* Psivida corp- announced 12-month follow-up data for company's durasert three-year treatment for posterior segment uveitis Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐